Join our presentation about severe hypertriglyceridemia (sHTG)

Sponsored by Ionis Pharmaceuticals®

PAID ADVERTISEMENT

sHTG is an underappreciated condition that affects millions and requires urgent action, as highlighted in expert publications by the American Heart Association and others. Patients with sHTG face life-threatening risks, including acute pancreatitis, atherosclerotic cardiovascular disease, and metabolic dysfunction–associated steatohepatitis (MASH), as well as cognitive and emotional impacts.^1-11

To learn more about the unmet need, urgent associated risks, and current treatment approaches for sHTG, please join our expert presentation on Sunday, November 9, 2025, at 11:15 AM - 12:00 PM CT in the Heart Theater II.

This presentation will feature Seth Baum, Chief Medical Officer of Flourish Research, Clinical Affiliate Professor of Cardiology at the Charles E. Schmidt College of Medicine at Florida Atlantic University, and a paid speaker for Ionis Pharmaceuticals, Inc.

Ionis will also be exhibiting at #AHA25. Come visit us at booth #4325. We look forward to meeting you.

To learn more about sHTG, visit TGAware.com.

This event is not part of the official Scientific Sessions 2025 as planned by the American Heart Association Committee on Scientific Sessions Program.

_References:
₁_{. Keirns BH, Sciarrillo CM, Koemel NA, Emerson SR. Fasting, non-fasting and postprandial triglycerides for screening cardiometabolic risk.}_{J Nutr Sci}_{. 2021;10:e75.}₂_{. Hegele RA, Ginsberg HN, Chapman MJ, et al. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management.}_{Lancet Diabetes Endocrinol.}_{2014;2(8):655-666.}₃_{. Virani SS, Morris PB, Agarwala A, et al. 2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology solution set oversight committee.}_{J Am Coll Cardiol.}_{2021;78(9):960-993.}₄_{. Nawaz H, Koutroumpakis E, Easler J, et al. Elevated serum triglycerides are independently associated with persistent organ failure in acute pancreatitis.}_{Am J Gastroenterol.}_{2015;110(10):1497-1503.}₅_{. Arca M, Veronesi C, D'Erasmo L, et al. Association of hypertriglyceridemia with all-cause mortality and atherosclerotic cardiovascular events in a low-risk Italian population: the TG-REAL retrospective cohort analysis.}_{J Am Heart Assoc.}_{2020;9(19):e015801.}₆_{. Christian JB, Bourgeois N, Snipes R, Lowe KA. Prevalence of severe (500 to 2,000 mg/dl) hypertriglyceridemia in United States adults.}_{Am J Col}_{. 2011;107(6):891-897.}₇_{. Skulas-Ray AC, Wilson PWF, Harris WS, et al. Omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association. Circulation. 2019;140(12):e673-e691.}₈_{. Newman CB, Blaha MJ, Boord JB, et al. Lipid management in patients with endocrine disorders: an Endocrine Society clinical practice guideline.}_{J Clin Endocrinol Metab}_{. 2020;105(12):3613-3682.}₉_{. Kirkpatrick CF, Sikand G, Petersen KS, et al. Nutrition interventions for adults with dyslipidemia: a clinical perspective from the National Lipid Association.}_{J Clin Lipidol.}_{2023;17(4):428-451.}₁₀_{. Gurevitz C, Chen L, Muntner P, Rosenson RS. Hypertriglyceridemia and multiorgan disease among U.S. adults.}_{JACC Adv.}_{2024;3(5):100932.}₁₁_{. Kessler AS, Zhang C, McStocker S, et al. Study-start characteristics of individuals with severe hypertriglyceridemia (sHTG) in an app-based home-reported outcomes study evaluating disease burden and treatment patterns. Abstract accepted for presentation at: PancreasFest; July 24-25, 2025; Pittsburgh, PA.}